{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T03:57:12Z","timestamp":1767585432268,"version":"3.37.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.msard.2025.106306","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T08:25:27Z","timestamp":1738225527000},"page":"106306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comparative effectiveness, persistence, and adherence of dimethyl fumarate and fingolimod in patients with multiple sclerosis in Japan: A cohort study"],"prefix":"10.1016","volume":"94","author":[{"given":"Sho","family":"Shimazaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7147-0737","authenticated-orcid":false,"given":"Toshiki","family":"Fukasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Okura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7477-4071","authenticated-orcid":false,"given":"Koji","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106306_bib0001","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat. Med."},{"key":"10.1016\/j.msard.2025.106306_bib0002","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/bcp.15071","article-title":"Comparative effectiveness of dimethyl fumarate in multiple sclerosis","volume":"88","author":"Bosco-L\u00e9vy","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.msard.2025.106306_bib0003","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40120-017-0064-x","article-title":"Comparative effectiveness research of disease-modifying therapies for the management of multiple sclerosis: analysis of a large health insurance claims database","volume":"6","author":"Boster","year":"2017","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106306_bib0004","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1007\/s00415-018-9083-5","article-title":"Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry","volume":"265","author":"Braune","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106306_bib0005","doi-asserted-by":"crossref","first-page":"e15017","DOI":"10.1016\/j.heliyon.2023.e15017","article-title":"Adherence to and persistence with lacosamide, perampanel, lamotrigine, and levetiracetam in adult patients with focal epilepsy in Japan: a descriptive cohort study using a claims database","volume":"9","author":"Chen","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.msard.2025.106306_bib0006","first-page":"457","article-title":"Measuring concurrent adherence to multiple related medications","volume":"15","author":"Choudhry","year":"2009","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.msard.2025.106306_bib0007","doi-asserted-by":"crossref","first-page":"e1016","DOI":"10.1212\/WNL.0000000000007043","article-title":"Validation of an algorithm for identifying MS cases in administrative health claims datasets","volume":"92","author":"Culpepper","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106306_bib0008","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2025.106306_bib0009","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000660","article-title":"Dimethyl fumarate vs fingolimod following different pretreatments: a retrospective study","volume":"7","author":"Diem","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106306_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210417","article-title":"A retrospective claims analysis: compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies","volume":"14","author":"Duquette","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2025.106306_bib0011","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.nurt.2007.07.008","article-title":"Corticosteroids for multiple sclerosis: I. Application for treating exacerbations","volume":"4","author":"Frohman","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2025.106306_bib0012","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1016\/j.jaip.2023.07.012","article-title":"Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with antibiotic use: a case-crossover study","volume":"11","author":"Fukasawa","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.msard.2025.106306_bib0013","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jclinepi.2021.08.028","article-title":"Causal analyses of existing databases: no power calculations required","volume":"144","author":"Hern\u00e1n","year":"2022","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.msard.2025.106306_bib0014","first-page":"844","article-title":"Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year","volume":"23","author":"Johnson","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.msard.2025.106306_bib0015","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s40120-022-00374-4","article-title":"Treatment status and healthcare cost trends for patients with multiple sclerosis in Japan: a claims database analysis","volume":"11","author":"Kawachi","year":"2022","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106306_bib0016","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","article-title":"Balancing covariates via propensity score weighting","volume":"113","author":"Li","year":"2018","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.msard.2025.106306_bib0017","first-page":"1653","article-title":"Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature","volume":"8","author":"Liz\u00e1n","year":"2014","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.msard.2025.106306_bib0018","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/ajhp\/zxab392","article-title":"Proportion of days covered as a measure of medication adherence","volume":"79","author":"Loucks","year":"2022","journal-title":"Am. J. Health. Syst. Pharm."},{"key":"10.1016\/j.msard.2025.106306_bib0019","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00415-016-8175-3","article-title":"Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study","volume":"263","author":"Miclea","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106306_bib0020","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/jgf2.422","article-title":"Data resource profile: JMDC claims database sourced from health insurance societies","volume":"22","author":"Nagai","year":"2021","journal-title":"J. Gen. Fam. Med."},{"key":"10.1016\/j.msard.2025.106306_bib0021","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1212\/NXI.0000000000000559","article-title":"Three cases of non-carryover fingolimod-PML: is the risk in Japan increased?","volume":"6","author":"Nakahara","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106306_bib0022","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1007\/s12325-018-0788-8","article-title":"72-Week safety and tolerability of dimethyl fumarate in Japanese patients with relapsing-remitting multiple sclerosis: analysis of the randomised, double blind, placebo-controlled, phase III APEX study and its open-label extension","volume":"35","author":"Ochi","year":"2018","journal-title":"Adv. Ther."},{"key":"10.1016\/j.msard.2025.106306_bib0023","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/cen3.12411","article-title":"Prevalence, treatments and medical cost of multiple sclerosis in Japan based on analysis of a health insurance claims database","volume":"8","author":"Ogino","year":"2017","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106306_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231846","article-title":"Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: real world evidence based on German claims data","volume":"15","author":"Ohlmeier","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2025.106306_bib0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.msard.2018.09.038","article-title":"Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US","volume":"27","author":"Ontaneda","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106306_bib0026","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.msard.2025.106306_bib0027","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12883-018-1220-3","article-title":"A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries","volume":"19","author":"Saida","year":"2019","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2025.106306_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101872","article-title":"Environmental risk factors for multiple sclerosis in Japanese people","volume":"38","author":"Sakoda","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106306_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research","volume":"66","author":"Stuart","year":"2013","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.msard.2025.106306_bib0030","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial","author":"Thomas","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2025.106306_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102741","article-title":"Use of a claims-based algorithm to estimate disease severity in the multiple sclerosis Medicare population","volume":"49","author":"Toliver","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106306_bib0032","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106306_bib0033","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.mayocp.2013.11.002","article-title":"Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies","volume":"89","author":"Wingerchuk","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.msard.2025.106306_bib0034","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2183\/pjab.98.026","article-title":"Clinical epidemiology and pharmacoepidemiology studies with real-world databases","volume":"98","author":"Yoshida","year":"2022","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T02:04:36Z","timestamp":1739498676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825000501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":34,"alternative-id":["S2211034825000501"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106306","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness, persistence, and adherence of dimethyl fumarate and fingolimod in patients with multiple sclerosis in Japan: A cohort study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106306"}}